| INTRODUC TI ON
Acute myocardial infarction (AMI) is a major cause of death and disability worldwide. As highly effective treatments are available, early and accurate detection of AMI is crucial (Nawar, Niska, & Xu, 2007; Anderson et al., 2013; Hamm et al., 2011; Kontos, Diercks, & Kirk, 2010; . Clinical assessment, the 12-lead electrocardiography (ECG), and cardiac troponin (cTn) form the pillars for the early diagnosis of AMI. While major advances have been achieved by the development of high-sensitive (hs-)cTn assays Safford et al., 2013; Reichlin et al., 2009; Keller et al., 2009 Keller et al., , 2011 Reichlin et al., 2012; Reiter et al., 2011; Gimenez et al., 2014; Reichlin et al., 2011; Haaf et al., 2012) , progress in the analysis and interpretation of the 12-lead ECG has been very limited over the past decade.
Nevertheless, the 12-lead ECG has unique logistic advantages as compared to high-sensitive (hs)-cTn testing. First, the ECG allows a rapid identification of patients presenting with ST-segment elevation myocardial infarction (STEMI) that derive a survival benefit from immediate coronary revascularization (Steg et al., 2012) . Second, the ECG can be performed immediately at presentation to the emergency department (ED), or even earlier in prehospital environment (Al-Zaiti, Martin-Gill, Sejdic, Alrawashdeh, & Callaway, 2015) . Turnaround time for hs-cTn is often more than 60 minutes. In addition, the release of cTn is a time-dependent phenomenon. Accordingly, two measurements are necessary in the vast majority of patients even with hs-cTn (Roffi et al., 2016) . Third, the ECG is universally available, while hs-cTn assays are still not available in many institutions worldwide. Accordingly, novel 12-lead ECG markers indicative of non-STelevation myocardial infarction (NSTEMI) could have an enormous potential to impact on the early diagnosis of NSTEMI.
The cardiac electrical biomarker (CEB) has been investigated as a novel ECG marker quantifying the multipolar versus dipolar activity of the heart with higher levels possibly indicating acute myocardial ischemic injury (Schreck & Fishberg, 2014) . Multipolar activity rises from myocardial ischemic injury altered polarization behavior of affected myocardial cells. Two pilot studies showed a high diagnostic accuracy of the CEB for the detection of AMI when compared to standard ST-segment analysis (Schreck & Fishberg, 2014 , 2015 . A third study found an association between increased CEB values and increased high-sensitive cardiac troponin I (hs-cTnI) levels (Tereshchenko, Gatz, Feeny, & Korley, 2014) .
The incremental diagnostic value of the CEB on top of standard ECG signals for the early diagnosis of NSTEMI is unknown. We therefore performed a large prospective diagnostic cohort study to examine the diagnostic value of the CEB, alone and in conjunction with conventional ECG criteria, in unselected patients presenting to the ED with symptoms suggestive of NSTEMI.
| ME THODS

| Study design and population
Advantageous Predictors of Acute Coronary Syndrome Evaluation (APACE) is an ongoing prospective international multicenter study designed to advance the early diagnosis of AMI (ClinicalTrials.gov registry, number NCT00470587) (Reichlin et al., 2009 Boeddinghaus et al., 2016 Boeddinghaus et al., , 2017 . Unselected patients presenting to the ED with symptoms suggestive of AMI (such as acute chest discomfort and angina pectoris) with an onset or peak within the last 12 hr and an age >18 were recruited. Patients with terminal kidney failure requiring dialysis were excluded. Further details regarding the study design can be found in the appendix.
For this analysis, only patients enrolled at the University Hospital Basel, Switzerland, were included. From April 2006 to May 2013, a total of 2121 unselected patients were enrolled. Patients without a digital 12-lead ECG (n = 350) or with insufficient ECG quality (n = 538) were excluded, as were patients with a QRS duration >120 ms (n = 103) on the presenting ECG. Furthermore, patients presenting with STEMI (n = 33) were excluded, because no additional ECG markers are needed in those patients. Patients with STelevations for other conditions such as for example, perimyocarditis however were included. This left 1097 patients eligible for this analysis ( Figure S1 ).
The study was carried out according to the principles of the Declaration of Helsinki and approved by the local ethics committees.
Written informed consent was obtained from all patients. The authors designed the study, gathered, and analyzed the data according to the STARD guidelines for studies of diagnostic accuracy (Bossuyt, 2003) .
| Adjudication of final diagnoses
Details on the adjudication of AMI have been published previously (Reichlin et al., 2009 (Reichlin et al., , 2009 and are given in Appendix S1. In brief, AMI was defined and hs-cTn levels interpreted as recommended in current guidelines (Thygesen et al., , 2007 Apple, Jesse, Newby, Wu, & Christenson, 2007) . AMI was diagnosed when there was evidence of myocardial necrosis with a significant rise and/or fall of hs-cTn levels in a clinical setting consistent with myocardial ischemia (Thygesen et al., , 2007 .
| Recording of ECGs for assessment of the CEB
At presentation to the ED, a digital 10 seconds, 12-lead resting ECG was recorded using the standard ECG machine (AT 110, Schiller AG, Baar, Switzerland). The sampling frequency was 500 Hz (signal bandwidth 0.05-150 Hz) and the resolution 1 μV/bit.
| Manual analysis of standard 12-lead ECGs
All 12-lead resting ECGs were manually interpreted in the ECG corelab at the University Hospital Basel by internal-medicine specialists blinded to the clinical and biochemical patient's details. ECG manifestations indicative of NSTEMI (ST-depressions and T-wave inversions) during manual interpretation were defined as recommended in current guidelines . Given that STEMI patients were excluded and the focus of the analysis was on the ECG detection of NSTEMI, we did not consider neither ST-elevations due to other conditions (such as perimyocarditis) nor hyperacute T waves as an indicator of NSTEMI. Figure 1b shows additionally an ischemic region.
| CEB computation
The change in surface potential is approximated by extra dipoles (three arrows). The overall surface potential is of multipolar nature.
CEB reflects the multipolar versus dipolar activity of the heart. The CEB is displayed as a numerical index with higher values representing a larger overall contribution of multipolar activity in the cardiac electrical field and hence a higher probability of acute myocardial ischemic injury, including AMI. Other than performing the CEB analyses, VectraCor ® had no role in the design of the study, the analysis of the data, the preparation of the manuscript, or the decision to submit the manuscript for publication.
| Blood sampling and laboratory methods
Blood samples for determination of hs-cTnT (Elecsys 2010, Roche Diagnostics) and hs-cTnI (Abbott Laboratories, IL) were collected in serum tubes at presentation to the ED. For the hs-cTnT assays, the limit of blank and limit of detection were determined to be 3 and 5 ng/L, respectively. The 99th-percentile of a healthy reference population was reported at 14 ng/L, with an imprecision corresponding to 10% CV at 13 ng/L (Giannitsis et al., 2010) . The hs-cTnI assay has a 99th percentile concentration of 26.2 ng/L with a corresponding coefficient of variation (CV) of <5% and a limit of detection (LoD) of 1.9 ng/L (Koerbin et al., 2012) . The estimate of the glomerular filtration rate (GFR) was calculated with the chronic kidney disease epidemiology collaboration equation (CKD-EPI) (Levey et al., 2009 ).
| Follow-up
After hospital discharge, patients were contacted after 3, 12, and 24 months by telephone calls or in written form. Information regarding death was furthermore obtained from the national registry on mortality, the hospital's diagnosis registry and the family physician's records. 
| Statistical analysis
Pearson, (1988). Sensitivities and specificities were compared using
McNemar's test (Trajman & Luiz, 2008) . Survival rates during 2 years of follow-up according to CEB tertiles were calculated and the logrank test was used to assess differences in survival between groups.
Multivariable Cox regression analysis was used to assess the prognostic value of the CEB after adjustment for age and cardiovascular risk factors including hypertension, diabetes, and coronary artery disease.
All hypothesis testing was two-tailed and p-values <.05 were considered statistically significant. All statistical analyses were performed using R 3.3.1 (R Core Team, 2016) with package Survival 2.39.5 (Therneau, 2015; Therneau & Grambsch, 2000) . 
| RE SULTS
| Characteristics of patients
| Levels of the CEB
Overall, the median CEB was 31 (IQR 17-65). The distribution of several baseline characteristics across CEB tertiles are shown in Table 2 .
Patients in higher CEB tertiles were older and had more cardiovascular risk factors as well as more often a history of CAD, AMI, and revas- Table 3 . The strongest predictor of CEB was found to be age followed by other cardiovascular risk factors.
TA B L E 1 Baseline characteristics of the patients in the study cohort Median hs-cTnT levels at admission to the ED were 7 ng/L (IQR 4-14) in the overall cohort. In patients with NSTEMI, levels were significantly higher compared to patients with other causes of chest pain (59 ng/L (IQR 23-157) vs. 6 ng/L (IQR 4-10), p < .001). A weak but statistically significant correlation between levels of hs-cTnT at admission to the ED and the CEB was found (r = .23, p < .001). For a subgroup of 864 patients (79%), hs-cTnI levels were available at presentation. Similarly, a weak but statistically significant correlation between levels of hs-cTnI at admission to the ED and the CEB was found (r = .24, p < .001). A significant difference in correlation between levels of hs-TnT and CEB, or between levels of hs-TnI and CEB, in the group of early presenters, patients presenting within 3 hr of onset of infarct symptoms, compared to late presenters, could not be found (p > .05).
| Diagnostic value of CEB levels
Overall, CEB levels were higher in patients with NSTEMI as com- 
| Incremental diagnostic value of the CEB in addition to conventional ECG interpretation for the diagnosis of NSTEMI
ECG changes indicative of NSTEMI, being ST-depressions or T-wave inversions, were found in 15% of the patients. NSTEMI was the final diagnosis in 39% of patients with ECG changes compared to 9% in those without (p < .001). The presence of any conventional ECG changes indicative of ischemia used as a binary variable reached a sensitivity of 43%, a specificity of 89%, a NPV of 91%, and a PPV of 39%.
A previously published score incorporating conventional ECG changes was calculated assigning 5 points for ST-depressions and 2 points for T-wave inversions (Abächerli et al., 2017) . This score Table 4b ,c.
| Prognostic value of the CEB for the prediction of mortality during follow-up
During 2 years of follow-up, there were 41 deaths with a median time to death of 349 days. Median CEB levels in deceased patients
were not significantly higher as compared to those in survivors (41 (IQR 18-82) vs. 31 (IQR 17-64), p = .23). Cumulative 2-year survival rates were 98%, 99%, and 94% according to tertiles of the CEB (p = .14), with a trend toward a higher mortality in patients in the third tertile compared to those in the first two tertiles (p = .06, Figure 3 ). However, after adjustment for important baseline variables in multivariable analysis (including age and cardiovascular risk factors such as hypertension, diabetes and coronary artery disease), this association was no longer observed (p = .86).
| D ISCUSS I ON
This large observational study assessed the diagnostic and prognostic value of the CEB, a novel ECG marker quantifying the multipolar activity of the heart for the diagnosis of NSTEMI. We report five major findings:
First, higher CEB values were found in patients that were older, had more cardiovascular risk factors, had more often a history of CAD, and had more often an AMI and a revascularization. Second, we found a weak correlation between levels of the CEB and hs-cTnT (r = .23, p < .001) as well as hs-cTnI (r = .24, p < .001). Third, CEB levels were significantly higher in patients with NSTEMI as compared to patients with other diagnoses (median 44 (IQR 21-98) vs. median 30 (IQR 16-61), p < .001).
The diagnostic accuracy of the CEB for the diagnosis of NSTEMI was moderate and similar to that of a score quantifying conventional ECG criteria (AUC 0.62 vs. 0.66, p = .16). Fourth, the combined use of the CEB and conventional ECG criteria increased the AUC from 0.66 to 0.71 (p < .001) and the sensitivity of the ECG for NSTEMI from 43% to 79% (p < .001). And fifth, there was a trend toward a higher mortality during 2-year follow-up in patients in the third tertile compared to F I G U R E 2 ROC curves at presentation for the diagnosis of NSTEMI. Area under the receiver operator characteristic (ROC) curves for a score incorporating conventional ECG criteria (CON ECG, green line) and the cardiac electrical biomarker (CEB, red line) at presentation, and the combination (blue line) of both in the diagnosis of non-ST-elevation myocardial infarction (NSTEMI)
those in the first two tertiles in univariate analysis. After adjustment for important baseline characteristics including age and cardiovascular risk factors, this association however was no longer observed.
Our findings have clinical implications. The ECG is the cornerstone of the diagnosis of STEMI patients. In NSTEMI patients, however, the conventionally recommended ECG markers of ischemia such as ST-segment depression and T-wave inversion have an acceptable specificity (89% in our study), but suffer from a low sensitivity (43% in our study). ECG markers with improved sensitivity for NSTEMI that are simple, readily available, and interpretable by a wide range of healthcare professionals, are a major unmet clinical need. The proposed CEB is a fully automated ECG marker representing multipolar versus dipolar activity in the cardiac electrical field, higher levels indicate a higher probability of NSTEMI. It is immediately and automatically calculated and reported by the ECG machine as a number, similar to the results of a blood test. Accordingly, its interpretation is simple and does not require additional training in ECG reading, which makes it suitable for use in the ED.
The findings of this large diagnostic study extend and corroborate previous pilot studies on the possible clinical utility of the CEB for the diagnosis of AMI (Schreck & Fishberg, 2014 , 2015 . In the largest published series to date, Schreck and Fishberg used 508 ECG obtained from various ECG databases and reported a sensitivity of 85%-94% and a specificity of 93% for the CEB to automatically detect standard ECG changes suggestive of myocardial ischemia (Schreck & Fishberg, 2014) . These results however must not be confounded with the diagnostic accuracy of the CEB for AMI: given that the gold standard was the presence of standard ECG changes suggestive of AMI during manual ECG interpretation, a NSTEMI TA B L E 4 (a) All patients, (b) patients without standard ECG changes indicative of NSTEMI, (c) patients with standard ECG changes indicative of NSTEMI F I G U R E 3 Kaplan-Meier curves for the cumulative survival according to CEB tertiles. Kaplan-Meier curves displaying survival during 24 months of follow-up according to CEB tertiles. Differences in survival were assessed using the log-rank test. p = .14 for the comparison of the CEB tertiles patient without ECG changes (which is the case in more than half of all NSTEMI patients) was classified as a non-AMI patient in that study. Furthermore, 70% of the AMI patients included were STEMIs.
Therefore, this study assessed the ability of the CEB to automatically detect standard ECG changes particularly in STEMI patients.
Our study extends the previous CEB-data by assessing the diagnostic value of the CEB for the first time in NSTEMI patients. Using a gold standard diagnosis incorporating a composite of hs-cTn levels, 12-lead ECG and all other available information as suggested in current guidelines we found significantly higher CEB values in NSTEMI patients compared to patients with other causes of chest pain. When used in addition to conventional ECG changes, the CEB allowed for a remarkable improvement of the ECG sensitivity for NSTEMI from 43% to 79%. The optimal cutoff found in our study (CEB 32) is remarkably lower compared to what has been found in the study by Schreck (CEB 95 for rule-in, CEB 65 for rule-out) (Schreck & Fishberg, 2014) and reflects the important difference in the gold standard used as well as the exclusion of STEMI patients in our study that accounted for 70% in the Schreck study (Schreck & Fishberg, 2014) . Tereshchenko et al., (2014) assessed the correlation of hs-cTnI and the CEB in patients with suspected AMI. While they did not find a correlation between the CEB levels and baseline hs-cTnI levels, they did find a correlation with hs-cTnI levels after 3 h. In contrast, we did find a weak but statistically significant correlation in our cohort between CEB levels and both hs-cTnT and hs-cTnI levels already at presentation. The only weak or even missing correlation is probably mainly explained by the fact that the CEB mainly reflects myocardial ischemia rather than necrosis such as the cardiac troponins. However, the diagnostic value of the CEB was not different in patients with active symptoms at the time of the ECG compared to those painfree. Our findings suggest that the CEB reflects a summary of the underlying cardiovascular risk factors rather than merely indicating myocardial ischemia.
It is important to highlight that as with any other novel diagnostic marker, the CEB should always be used in conjunction with (and certainly not replace) all other available information from clinical assessment, blood tests and also from the standard ECG. The particular added value of the CEB would be to assist in the very early identification of NSTEMI patients without standard ECG changes but typical symptoms even before the troponin results become available.
However, even though the use of the CEB in addition to conventional ECG criteria improved the diagnostic accuracy for NSTEMI (increase in AUC from 0.66 to 0.71 p < .001), NSTEMI was diagnosed in only 20% of patients in the third CEB tertile, indicating a lot of false positive cases. Despite the increase in ECG sensitivity from 43% to 79% (p < .001), NSTEMI was still diagnosed in 10% of patients in the lowest CEB tertile. Accordingly, the diagnostic performance is clearly inferior compared to diagnostic algorithms based on highsensitive troponins Boeddinghaus et al., 2016) , and the search for other, better ECG markers of NSTEMI must go on in order to increase the clinical significance of novel automated ECG markers indicative of NSTEMI.
| Limitations
Potential limitations of the present study merit consideration. First, we cannot comment on the value of the CEB in patients with a wide QRS complex >120 ms, because those patients were excluded from analysis. Given that bundle branch blocks result in remarkable changes of both depolarization as well as repolarization, we assume that the resulting changes to the cardiac electrical field make diagnostic value of the CEB in those patients unlikely. Second, there
were no imaging data available to assess the association of left ventricular hypertrophy or old scars with CEB levels. Third, we did not record serial ECGs in our patients. Therefore, we cannot asses dynamic CEB changes nor CEB changes after resolution of ischemia.
Serial ECGs could have increased the diagnostic value, as well as the pathophysiological understanding of the CEB Marker. Fourth, this is a single center study, and our results require validation in independent cohorts. Fifth, we have assessed the value of the CEB in patients at rest in the ED. Whether or not the marker would be helpful to detect myocardial ischemia in patients undergoing ECG stress testing cannot be answered from our data.
| CON CLUS ION
In conclusion, the CEB, an ECG marker quantifying the multipolar versus dipolar activity of the heart, significantly improves the diagnostic accuracy of the ECG for the diagnosis of NSTEMI and increases the ECG sensitivity from 43% to 79% when used in addition to conventional ECG changes. However, the search for other, better ECG markers of NSTEMI must go on in order to increase the clinical significance of novel automated ECG markers indicative of NSTEMI.
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